We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+2.93%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$182M
AUM Growth
-$9.72M
(-5.1%)
Cap. Flow
-$9.6M
Cap. Flow
% of AUM
-5.28%
Top 10 Holdings %
Top 10 Hldgs %
6.2%
Holding
508
New
65
Increased
160
Reduced
215
Closed
68
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dow Inc
DOW
|
+$1.19M |
| 2 |
Progressive
PGR
|
+$963K |
| 3 |
Hershey
HSY
|
+$960K |
| 4 |
DexCom
DXCM
|
+$934K |
| 5 |
Copart
CPRT
|
+$930K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lennar Class A
LEN
|
+$952K |
| 2 |
TJX Companies
TJX
|
+$909K |
| 3 |
Ameriprise Financial
AMP
|
+$902K |
| 4 |
Abbott
ABT
|
+$892K |
| 5 |
Home Depot
HD
|
+$885K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.65% |
| 2 | Financials | 14.09% |
| 3 | Technology | 11.21% |
| 4 | Energy | 10.21% |
| 5 | Materials | 8.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DVAX
376
DELISTED
Dynavax Technologies
DVAX
| $85.9K | 0.05% |
8,756
-3,371
| -28% | -$36K |
|
|
DICE
377
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $85.4K | 0.05% |
2,980
-1,147
| -28% | -$34K |
|
378
Dyne Therapeutics
DYN
$4.68B
| $84.5K | 0.05% |
7,335
-2,815
| -28% | -$36.6K |
|
379
Prothena Corp
PRTA
$448M
| $84.5K | 0.05% |
1,743
-673
| -28% | -$35.6K |
|
380
Edgewise Therapeutics
EWTX
$4.28B
| $83.4K | 0.05% |
12,507
-4,807
| -28% | -$44.6K |
|
381
Vaxcyte
PCVX
$7.65B
| $82.9K | 0.05% |
2,211
-853
| -28% | -$36.2K |
|
382
IDEAYA Biosciences
IDYA
$3.43B
| $82K | 0.05% |
5,972
-2,287
| -28% | -$38.1K |
|
|
NUVL
383
DELISTED
Nuvalent
NUVL
| $81.6K | 0.04% |
3,127
-1,203
| -28% | -$35.6K |
|
384
Regenxbio
RGNX
$616M
| $80.5K | 0.04% |
4,257
-1,636
| -28% | -$36.2K |
|
|
EQRX
385
DELISTED
EQRx, Inc. Common Stock
EQRX
| $80.4K | 0.04% |
41,463
-15,942
| -28% | -$36.3K |
|
386
Nektar Therapeutics
NKTR
$2.39B
| $79K | 0.04% |
7,494
+133
| +2% | +$4.02K |
|
387
Arrowhead Research
ARWR
$12.1B
| $78.2K | 0.04% |
3,078
-1,186
| -28% | -$37.3K |
|
|
AMRS
388
DELISTED
Amyris Inc.
AMRS
| $78.2K | 0.04% |
57,485
-22,100
| -28% | -$31.6K |
|
|
NGM
389
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $77.2K | 0.04% |
18,916
-7,265
| -28% | -$33.6K |
|
390
Atea Pharmaceuticals
AVIR
$370M
| $76.9K | 0.04% |
22,948
-8,814
| -28% | -$35.8K |
|
391
Rocket Pharmaceuticals
RCKT
$343M
| $76.1K | 0.04% |
4,441
-1,713
| -28% | -$33.5K |
|
392
Denali Therapeutics
DNLI
$3.79B
| $75.9K | 0.04% |
3,293
-1,259
| -28% | -$34.6K |
|
393
Atara Biotherapeutics
ATRA
$72.6M
| $75.6K | 0.04% |
1,043
-401
| -28% | -$38.9K |
|
394
AbCellera Biologics
ABCL
$1.65B
| $75.3K | 0.04% |
9,983
-3,844
| -28% | -$34.9K |
|
395
Codexis
CDXS
$158M
| $75.1K | 0.04% |
18,136
-6,966
| -28% | -$36.5K |
|
396
AnaptysBio
ANAB
$1.54B
| $75K | 0.04% |
3,448
-1,326
| -28% | -$32.2K |
|
397
Recursion Pharmaceuticals
RXRX
$1.58B
| $73.9K | 0.04% |
11,085
-4,257
| -28% | -$33.8K |
|
398
Arvinas
ARVN
$530M
| $73.4K | 0.04% |
2,688
-1,033
| -28% | -$32.6K |
|
399
Nurix Therapeutics
NRIX
$2.45B
| $72.6K | 0.04% |
8,181
-3,151
| -28% | -$32.8K |
|
400
Immatics
IMTX
$1.23B
| $72.2K | 0.04% |
10,470
-4,030
| -28% | -$33K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
RC
Virtus ETF Advisers's Q1 2023 Portfolio in Review
As of Q1 2023, Virtus ETF Advisers held 508 positions worth $182M, down 5.1% from $191M the previous quarter. Its ten largest holdings account for 6.2% of the portfolio.
Virtus ETF Advisers withdrew a net $9.6M in Q1 2023, closing 68 positions and reducing 215 holdings. Its most notable exit was Lennar Class A, an estimated $952K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 26% of assets, down from 27% a quarter earlier, followed by Financials and Technology.
Against the trend, Virtus ETF Advisers opened a new position in Dow Inc worth $1.16M.
- Virtus ETF Advisers's largest Q1 2023 buy was Dow Inc: 21,099 shares worth $1.16M.
- Virtus ETF Advisers added most to Devon Energy in Q1 2023, an estimated $447K increase.
- Virtus ETF Advisers's biggest Q1 2023 reduction was LyondellBasell Industries, cutting an estimated $514K.
- Virtus ETF Advisers fully exited Lennar Class A in Q1 2023, selling an estimated $952K.
- Virtus ETF Advisers's ten largest holdings make up 6.2% of its $182M portfolio in Q1 2023.
- Virtus ETF Advisers opened 65 new positions and closed 68 in Q1 2023.
- Virtus ETF Advisers's portfolio value fell 5.1% quarter-over-quarter to $182M.
Based on Virtus ETF Advisers's 13F filing for Q1 2023, filed 15 May 2023.